Dolutegravir/lamivudine
Dolutegravir/lamivudine (trade name Dovato) is a combination drug for the treatment of HIV/AIDS. It was approved for use in the United States in April 2019.[1] It contains dolutegravir, an integrase inhibitor, and lamivudine, a reverse-transcriptase inhibitor.
| Combination of | |
|---|---|
| Dolutegravir | Integrase inhibitor |
| Lamivudine | Reverse-transcriptase inhibitor |
| Clinical data | |
| Trade names | Dovato |
| Identifiers | |
| KEGG | |
References
- "FDA approves first two-drug complete regimen for HIV-infected patients who have never received antiretroviral treatment" (Press release). Food and Drug Administration. Retrieved April 9, 2019.
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.